Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis)

Trial Profile

A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CPI 0610 (Primary) ; Ruxolitinib
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders
  • Focus Proof of concept; Therapeutic Use
  • Acronyms MANIFEST
  • Sponsors Constellation Pharmaceuticals
  • Most Recent Events

    • 18 Nov 2019 Results (n=11, data cut off: 27 June 2019 ) published in the ASH annual meeting
    • 14 Nov 2019 Results (n=48, data cut off:27 June 2019 ) presented at ASH annual meeting.
    • 06 Nov 2019 According to a Constellation Pharmaceuticals media release, the company expanded Arm 3 for JAK-inhibitor-naive patients from 43 to up to approximately 100 patients and Cohort 2A for TD ruxolitinib-refractory or intolerant patients being treated with CPI-0610 + ruxolitinib. The company may expand Cohort 1A for TD ruxolitinib-refractory or -intolerant patients being treated with CPI-0610 monotherapy, from 16 to up to approximately 60 patients in each cohort.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top